Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Dominated by oil malaise

Karoon Energy
3:27pm
April 17, 2025
A solid 1Q25 result given the planned (and flagged) maintenance shutdown at Karoon’s flagship Bauna operation, with 1Q25 marginally ahead of expectations. The Bauna FPSO reached 92.3% uptime in the quarter, excluding the shutdown, compared to 84.6% in the prior quarter. Karoon is moving Neon into a define phase, increasing FY25 capex by ~6%. All production and cost guidance has been maintained. Maintain ADD rating with a lower A$2.25ps target price (was A$2.40).

3Q25 update

Challenger Financial Svcs
3:27pm
April 17, 2025
CGF has released its 3Q25 update. The key takeaway, in our view, was CGF has narrowed its FY25 NPAT guidance range to A$450m-A$465m (previously A$440m-A$480m), which indicates increased confidence with the current year outlook. We make relatively nominal changes to our CGF FY24F/FY25F EPS of ~-1%/-2%. Our PT rises to A$7.51, with our earnings changes offset by a valuation roll-forward. We think CGF has shown good earnings momentum in recent periods (3 year NPAT CAGR +11%), and with the stock trading on an undemanding ~11x FY25F PE multiple, we see further upside. ADD maintained.

1H25 earnings beat, FY26 ROE target offers upside

Bank of Queensland
3:27pm
April 16, 2025
1H25 EPS and DPS growth beat expectations. BOQ stands firm on its FY26 ROE and CTI targets, offering material upside to our upgraded forecasts and a potential valuation of >$10/sh if they are achieved. Our base case is more conservative, hence we retain a HOLD with 12 month potential TSR of c.8% at current prices. Upgraded cash EPS by 3%/6%/9% for FY25/26/27F, as we downgrade our NIM forecast, upgrade asset base growth (stronger loan growth), and reduce LIE (lower-for-longer). DCF valuation lifts 1% to $7.04/sh, as the earnings upgrade is offset by higher CET1 investment to meet the growth in RWA. Potential >$10/share valuation based on application of a P:BV vs ROE peer group regression.

Steel market pain helps Pilbara transition

Rio Tinto
3:27pm
April 16, 2025
As expected a softer start with a weather-impacted 1Q25 Pilbara performance. Copper was a bright spot coming in ahead as OTUG continues to shine. We continue to see RIO as trading below value while offering appealing relative safety in current dynamic market conditions. Maintain ADD rating, A$123 PT.

Highly leveraged to continued gold price strength

Evolution Mining
3:27pm
April 15, 2025
EVN delivered another strong production and cash flow result. Deleveraging continued at a rapid pace with net debt reducing 25% qoq and gearing now at ~19%. Strong cash flows give way to accelerated repayments of EVN’s term loans which will assist in an even more rapid deleveraging. We maintain our Hold rating with a A$8.00ps TP (previously A$5.90ps).

Partnership to bring Sports Direct Down Under

Accent Group
3:27pm
April 15, 2025
After much media speculation and following the initial strategic investment from UK retailer Frasers Group (FRAS.LSE) in August 2024, AX1 today announced it has made a long term agreement to roll out stores under Frasers’ flagship brand Sports Direct in Australia and New Zealand. The long term agreement will see AX1 rollout at least 50 stores over the next 6 years with an aspirational target of 100 stores in time. Frasers Group will increase its shareholding in AX1 to 19.57% (from 14.57%) via a placement of 35.2m shares at $1.718 per share (a 3.5% discount to Friday’s close). Proceeds from the placement ($60.4m) will be used to fund the initial roll-out of Sports Direct. AX1’s CEO, Daniel Agostinelli, has committed to remaining as CEO for at least another 3 years. We have lowered our EPS by 3% in FY25 and 2% in FY26. We have included a modest contribution for Sports Direct rollout into FY26/27. We have retained our HOLD recommendation, with a $2.00 price target, down from $2.20.

FDA approval- revolutionising heart failure treatment

EBR Systems
3:27pm
April 15, 2025
Despite what appears to be tumultuous time at US regulatory agencies, EBR delivered on its timeline and has received FDA’s blessing for its cardiac resynchronisation therapy (CRT) system (known as WiSE) for the treatment of heart failure, a major milestone after more than two decades in development. Encouragingly, contraindications are limited and the label aligns with the initially targeted cUS$3.6bn key market segments, including use with leadless pacemakers, with investor concern that Abbott’s Aveir was excluded, pending additional data, misplaced, in our view. We also believe the post-marketing study should not be viewed with any apprehension, as it is merely par for the course and in fact, should help strengthen the use case and label expansions over time. We continue to view commercial and manufacturing readiness, along with a reimbursement path that is both streamlined and incentivised, as helping to smooth the transition from developmental stage into a commercially viable medical device business. We make no changes to CY25-26 forecasts, and maintain our A$2.86 DCF-based valuation. With clinical risk now mitigated we move to an Add rating (from Speculative Buy).

1Q25 update

MA Financial Group
3:27pm
April 14, 2025
MAF has released its 1Q25 update. This showed that momentum is still generally reasonable across the MAF franchise in our view.  In summary, whilst Asset Management net flows were a bit below our expectations, MA Money lending growth was better than we expected. We downgrade our MAF FY25F/FY26F EPS by 4%-7% on lower Asset Management net inflows and AUM forecasts. Our PT is reduced to A$8.11 (previously A$8.92). We think MAF management are building a strong, differentiated franchise. We maintain our ADD recommendation, with significant upside existing to our price target.

Collateral damage

Reliance Worldwide
3:27pm
April 14, 2025
RWC’s share price has fallen 12% since the beginning of April and 23% over the past 3 months as uncertainty continues in relation to US tariffs on Chinese goods. US tariffs on Chinese goods (except certain consumer electronics) currently stands at 145%, although given recent history, this can turn on a dime and could depend on whether President Trump and President Xi can reach a deal. RWC predominantly manufactures key products in each region for sale within that region. However, cost of goods sold (COGS) for its Americas division includes ~US$120m in purchases from China that are subject to tariffs. We provide a scenario analysis on the impact on FY26F EBITDA for varying levels of US tariffs on Chinese goods against RWC’s ability to offset. Due to the highly uncertain outlook, we move our rating on RWC to Hold (from Add) as we await further clarity on tariffs and what this could mean for operating costs as well as revenue given risks to the global macroeconomic backdrop. We make no changes to EBITDA in FY25F but decrease both FY26F and FY27F by 7%. Our target price declines to $4.15 (from $5.80 previously).

Truly ground breaking moment

Imricor Medical Systems
3:27pm
April 13, 2025
The medical team at Amsterdam University Medical Centre have performed the first-in-human ventricular ablation guided by real time interventional cardiac magnetic resonance (iCMR) with IMR’s technology including its NorthStar mapping system. This has been a 20 year journey by IMR’s founder Steve Wedan and his team and marks a truly ground breaking moment in medical history. Following the recent A$70m capital raise, IMR is in a strong financial position to achieve a number of key catalysts including the approval of the NorthStar mapping system in Europe and US, secure approval in the US for atrial flutter, complete the Europe trail for ventricular tachycardia and drive sales in Europe and Middle East. We have made no changes to forecasts or our target price of A$2.28. IMR is a key pick in the emerging healthcare space and we maintain our speculative buy recommendation.

News & Insights

The US economy is growing strongly at 2.34% in Q2 2025 but is expected to slow to 1.4% in 2025, with falling interest rates and a weaker US dollar likely to boost commodity prices, benefiting Australian markets. Michael Knox discusses.

We think the US economy is currently experiencing solid growth, with data from the Chicago Fed  National Activity Index indicating an annual growth rate of just above  2%. This aligns with projections from other parts of the Federal Reserve System, such as the New York Fed. The New York Fed’s weekly Nowcast, updated every Friday, estimates that for the second quarter of 2025, the US economy is growing at an annualised rate of 2.34%, surpassing the 2% mark. This robust growth is consistent with our model’s view that the US economy is now performing strongly. However, we anticipate a slowdown in the second half of 2025.

On 18 June the Fed released its Summary of Economic Projections  with the Federal Reserve’s  forecasting US GDP growth to drop to 1.4% in 2025, down from their March estimate of 1.7%. Looking further ahead, growth is expected to pick up slightly to 1.6% in 2026 and 1.8% in 2027, aligning with the long-term trend growth rate of around 1.8%. We believe this recovery trend could be even  higher,  driven by reduced regulation under the second Trump administration and aggressive tax write-offs for companies building factories in the US, allowing 100% write-offs for equipment and buildings in the first year. This policy should foster stronger systemic growth.

Economic Projections of the Federal Reserve

The Fed expects that as the economy slows,  unemployment is projected to rise to 4.5% from the current level of 4.2%. Inflation, measured by the Consumer Price Index (CPI), is running at 3.5% this year, approximately 50 basis points higher than the Personal Consumption Expenditures (PCE) index of 3.0%, with 1.6% of this  inflation  attributed to tariffs. The Fed expects PCE Inflation  to ease to 2.4% in 2026 and 2.1% in 2027. The Federal Reserve anticipates cutting the effective  federal funds rate, currently at 433 basis points (according to the New York Fed), by 50 basis points by the end of 2025, followed by an additional 25 basis points in each of the next two years. This aligns with our own Fed Funds rate  model’s current equilibrium federal funds rate of  3.85% . The Fed Outlook  supports our scenario of a slowing US economy and rate cuts in the second half of 2025 and beyond. A falling US dollar is then expected to exert upward pressure on commodity prices, benefiting Australian Equity markets.

Taking questions during the Press Conference after releasing the Fed statement  ,Federal Reserve Chair Jay Powell,   addressed the certainty and uncertainty surrounding the inflationary effects of tariffs. Initially, at the start of 2025, the inflationary impact of tariff policies was unclear, but three months of favourable inflation data have provided this clarity, indicating that the inflationary effects are less severe than anticipated. Powell noted that the Feds own uncertainty on the inflationary effects of  tariffs  peaked in April 2025, and the Federal Reserve now has a clearer understanding that  the inflation effects, are lower than initially expected.

The Fed view  supports our own scenario of a slowing US economy in the second half of 2025, allowing for Fed rate cuts  . This in turn should then lead to  a falling US dollar, which we in turn  expect to drive rising commodity prices.

Read more
The Your Wealth publication is our half yearly scrutiny into current affairs for wealth management. Our latest Issue 29 is out now.

The second half of 2025 will be an interesting time for everyone. Geopolitical uncertainty prevails. How will all of this impact the Australian investor and in particular, their wealth and retirement savings? Whether you are an accumulator, saving for short- and long-term goals, or a retiree, hoping for a comfortable retirement, the ability to manage this uncertainty will be key.

When we published the previous Your Wealth – First Half 2025, the Division 296 Bill (Div296) was also facing uncertainty. The Bill was eventually blocked in the Senate prior to the Federal Election. The Labor Party succeeded in winning so it’s Ground Hog Day for Div296. The Government doesn’t have the numbers in the Senate to pass the Bill without support from other parties. The Greens are the likely negotiating party but will undoubtably have their own agenda. Regardless, there is a high probability this legislation will be passed once Parliament resumes.

Our message to our clients is to wait until we know more details and to not act in haste.

In addition to our Feature Article which provides further insights on Div296, this edition also Spotlights the Aged Care changes due this year, with the start date pushed back to 1 November.

We hope readers enjoy this edition of Your Wealth.


Morgans clients receive exclusive insights such as access to our latest Your Wealth publication. Contact us today to begin your journey with Morgans.

      
Contact us
      
Read more
Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more